Table 2.
Patients demographics
| Variable |
Group |
Total (n = 200) | P value | |
| Downstaging (n = 64) | Bridging (n = 136) | |||
| Gender (Male), n (%) | 53 (82.8) | 112 (82.4) | 165 (82.5) | 0.936 |
| Age (yr) (mean ± SD, range) | 57.6 ± 6.9 (41-71) | 58.2 ± 8.8 (27-77) | 58.0 ± 8.2 (27-77) | 0.6261 |
| Etiology, n (%) | 0.0692 | |||
| Hepatitis B | 7 (10.9) | 5 (3.7) | 12 (6.0) | |
| Hepatitis C | 43 (67.2) | 78 (57.4) | 121 (60.5) | |
| Hepatitis B/C | 1 (1.6) | 6 (4.4) | 7 (3.5) | |
| Alcohol | 6 (9.4) | 26 (19.1) | 32 (16.0) | |
| Alcohol/Hepatitis | 2 (3.1) | 2 (1.5) | 4 (2.0) | |
| Other | 5 (7.8) | 19 (14.0) | 24 (12.0) | |
| Child-Pugh score, n (%) | 0.2442 | |||
| A (5-6) | 24 (41.4) | 72 (53.7) | 96 (50.0) | |
| B (7-9) | 30 (51.7) | 52 (38.8) | 82 (42.7) | |
| C (10-15) | 4 (6.9) | 10 (7.5) | 14 (7.3) | |
| MELD, mean ± SD | 13 (7-28) | 11 (6-23) | 12 (6-28) | 0.0553 |
| AFP (ng/dL) (mean ± SD, range) | 12.3 (0.9-22.411) | 10.1 (0.6-12.784) | 11.0 (0.6-22.411) | 0.3353 |
| Coagulopathy, n (%) | 0.095 | |||
| No | 41 (64.1) | 70 (51.5) | 111 (55.5) | |
| Yes | 23 (35.9) | 66 (48.5) | 89 (44.5) | |
| Thrombocytopenia, n (%) | 0.297 | |||
| No | 27 (42.2) | 47 (34.6) | 74 (37.0) | |
| Yes | 37 (57.8) | 89 (65.4) | 126 (63.0) | |
| HCC multifocal, n (%) | < 0.001 | |||
| Single tumor | 14 (21.9) | 89 (65.4) | 103 (51.5) | |
| Multinodular | 50 (78.1) | 47 (34.6) | 97 (48.5) | |
| Number of nodules (mean ± SD, range) | 2 (1-9) | 1 (1-3) | 1 (1-9) | < 0.0013 |
| Maximal tumor diameter (mean ± SD, range) | 8.09 ± 2.75 (4.6-17.2) | 3.75 ± 1.20 (1.4-7.5) | 5.14 ± 2.74 (1.4-17.2) | < 0.0011 |
| Pseudocapsule, n (%) | 0.118 | |||
| No | 9 (17.0) | 30 (28.3) | 39 (24.5) | |
| Yes | 44 (83) | 76 (71.7) | 120 (75.5) | |
| Vascular lake phenomenon, n (%) | < 0.001 | |||
| No | 42 (65.6) | 119 (87.5) | 161 (80.5) | |
| Yes | 22 (34.4) | 17 (12.5) | 39 (19.5) | |
Chi-squared test.
1
Student’s t test;
2
Likelihood ratio test;
3
Mann-Whitney test. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; MELD: Model for End-Stage Liver Disease.